Acquired defects of fibrinolysis associated with thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 4, 1999, Pages 367-374

  Fareed, Jawed ^a,c   Hoppensteadt, Debra A ^a   Jeske, Walter P ^a   Ahmad, Sarfraz ^a   Bick, Rodger L ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplasmin; Embolism; Fibrinolysis; Hypercoagulability; t PA; Thrombosis; u PA

Indexed keywords

ACTIVATED PROTEIN C; ANTINEOPLASTIC AGENT; APROTININ; ASPARAGINASE; BLOOD CLOTTING FACTOR 8; CYTOKINE; ERYTHROPOIETIN; HORMONE; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR;

BLOOD COMPONENT THERAPY; BLOOD TOXICITY; BLOOD VESSEL OCCLUSION; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; THROMBOSIS;

EID: 0032756460     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994940     Document Type: Review

References (57)

1. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984;10:24-41
2. Winman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990;16:207-216
3. Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Hemost 1984;10:18-23
4. Kaplan AP, Austen F. The fibrinolytic pathway of human plasma: Isolation and characterization of the plasminogen proactivator. J Exp Med 1972;135:1378-1393
5. Bachmann F, Kruithof KO. Tissue plasminogen activator: Chemical and physiological aspects. Semin Thromb Hemost 1984;10:6-17
6. Robbins KC, Barlow GH, Hguyen G, Comparison of plasminogen activators. Semin Thromb Hemost 1987;13:131-138
7. Bick RL. Disorders of Thrombosis and Hemostasis. Chicago: ASCP Press; 1992;220-223
8. Krudryk B, Collen D, Woods KR, et al. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem 1974;249: 3322-3225
9. Murano G. The molecular structure of fibrinogen. Semin Thromb Hemost 1974;1:1-31
10. Kowalski E. Fibrinogen derivatives and their biological activity. Semin Hematol 1968;5:45-51
11. Marder VJ, Shulman NR. High molecular weight derivatives of human fibrinogen produced by plasmin: Mechanism of their anticoagulant activity. J Biol Chem 1969;244:2120-2124
12. Screiber AD. Plasma inhibitors of the Hageman factor dependent pathways. Semin Thromb Hemost 1976;3:43-51
13. 2-macroglobulin. Acta Univ Lund Sect 1967;2:2-10
14. Astedt B, Isacson S, Nilsson IM, et al. Thrombosis and oral contraceptives: Possible predispostion. Br Med J 1973;4: 631-634
15. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989;9:87-115
16. Castellino FJ. Biochemistry of human plasminogen and PAI, Semin Thromb Hemost 1984;10:18-23
17. Booth NA, Anderson JA, Bennett B. Platelet release protein which inhibits plasminogen activators. J Clin Pathol 1985;38: 825-830
18. Laug EW. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells, Thromb Res 1985;53: 165-171
19. Vasalli JD, Dayer JM, Wohlwend A, et al. Concomitant secretion of prourokinase and of plasminogen activator-specific inhibitor by cultured human monocytes-macrophage, J Exp Med 1984;159:1653-1668
20. Kopitar M, Rozman B, Babnik J, et al. Human leukocyte urokinase inhibitor: Purification, characterization and comparative studies against different plasminogen activators. Thromb Haemost 1985;54:750-755
21. Bachmann F, Fibrinolysis. In: Verstraete M, Vermylen J, Linjnen R, Arnout J (eds). Thrombosis and Haemostasis. Leuven: Leuven University Press; 1987:277-292
22. Nilsson IM, Krook H, Sternby NH, et al. Severe thrombotic disease in a young man with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand 1961;169:323-337
23. Nguyen G, Horellou MH, Kruithof EKO, Conard J, Samama M. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: A study in 83 patients with confirmed deep vein thrombosis. Blood 1988;72:601-605
24. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep vein thrombosis. Thromb Haemost 1987;57:67-72
25. Rocha E, Alfaro MJ, Paramo JA, Canadell JM. Pre-operative identification of patients at high risk of deep vein thrombosis despite prophylaxis in total hip replacement. Thromb Haemost 1988;59:93-95
26. Grimaudo V, Kruithof EKO, Stiekma JCJ, Bachmann F. High pre-operative plasminogen activator inhibitor levels are correlated with post-operative deep vein thrombosis in total hip replacement. Thromb Haemost 1989;62 (Abstr 96)
27. Menon IS, Peberdy M, Rannie RH, et al. A comparative study of blood fibrinolytic activity in normal women, pregnant women and women on oral contraceptives. J Obstet Gynaecol Br Commonw 1970;77:752-756
28. Bonnar J, Prentice CR, McNicol GP, et al. Haemostatic mechanism in the uterine circulation during placental separation. Br Med J 1970;1:564-567
29. Astedt B, Isacson S, Nilsson IM, et al. Thrombosis and oral contraceptives: Possible predisposition. Br Med J 1973;4:631-634
30. Gordon-Smith IC, Hickman JA, LeQuesne LP. Postoperative fibrinolytic activity and deep vein thrombosis. Br J Surg 1974; 61:213-218
31. Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976;2: 910-912
32. Comp PC, Jacobs RM, Taylor FB Jr. The dilute whole blood clot lysis assay: A screening method for identifying post-operative patients with a high incidence of deep venous thrombosis. J Lab Clin Med 1979;93:120-127
33. Crandon AJ, Peel KR, Anderson JA, et al. Postoperative deep vein thrombosis: Identifying high-risk patients, Br Med J 1980;192:343-344
34. Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease and associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 1978;203:477-480
35. Aoki N, Moroi M, Sakata Y, et al. Abnormal plasminogen. J Clin Invest 1978;51:1186-1195
36. Inglesby TW, Singer JW. Abnormal fibrinolysis in familial pulmonary hypertension. Acta Med Scand 1978;203:477-480
37. Zoller B, Garcia de Frutos P, Dahlbäck B. A common allele in the promotor of the plasminogen activator inhibitor (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost 1998;79:802-807
38. Rifon J, Paramo JA, Panizo C, Montes R, Rocha E. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Atheroselerosis 1998;137:258-263
39. Killewich LA, Macko RF, Gardner AW, et al. Defective fibrinolysis occurs after infrainguinal reconstruction. J Vasc Surg 1997;25:858-864
40. Boudaoud L, Roussi J, Lortat-Jacob S, et al. Endothelial fibrinolytic reactivity and the risk of deep vein thrombosis after spinal cord injury. Spinal Cord 1997;35:151-157
41. Ossei-Gerning N, Moayyedi P, Smith S, et al. Helicobacter pylori infection is related to atheroma in patients undergoing coronary angioplasty. Cardiovasc Res 1997;35:120-124
42. Glueck CJ, Fontaine RN, Gupta A, Alasmi M. Myocardial infarction in a 35-year old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C. Metabolism; Clin Exp 1997;46:1470-1472
43. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79:12-16
44. Carmeliet P, Collen D. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol 1997;8:118-125
45. Lowe GD. Etiopathogenesis of cardiovascular disease: Hemostasis, thrombosis, and vascular medicine. Ann Periodontol 1998;3:121-126
46. Dimmitt SB, Rakic V, Puddey IB, et al. The effects of alcohol on coagulation and fibrinolytic factors: A controlled trial. Blood Coag Fibrinolysis 1998;9:39-45
47. Killewich LA, Gardner AW, Macko RF, et al. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 1998;27:645-650
48. Bankl HC, Radaszkiewicz T, Pikula B, et al. Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. Human Pathol 1997;28:1283-1290
49. Sundell IB, Marzec UM, Kelly AB, et al. Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in non-human primates. Circulation 1997;96:941-948
50. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057-2063
51. Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factory pathway inhibitor and increased plasminogen activator inhibitor-I in dyslipidemias. Arteriosclerosis Thromb Vasc Biol 1996;16:77-81
52. Bick RL, Ancypa D. Blood protein defects associated with thrombosis: Laboratory assessment. Clin Lab Med 1995; 15:125-163
53. Schubring C, Grülich-Henn J, Bauer S, Gips H, Müller-Berghaus G. Influence of hysterectomy on the fibrinolytic activity of plasma of women with intact ovarian function. Eur J Obstet Gynaecol Reprod Biol 1995;59:39-43
54. Kinugasa K, Kamata I, Hirotsune N, et al. Early treatment of subarachnoid hemorrhage after preventing rerupture of an aneurysm. J Neurosurg 1995;83:39-41
55. Bauer, K. Inherited and acquired hypercoagulale states. In: Loscalzo et al., eds. Thrombosis and Hemorrhage (2nd Ed.), Philadelphia, PA:Lippincott, Williams and Wilkens, 1998; 863-900
56. Callas DD, Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors: Implications in anticoagulant and thrombolytic therapy. Thromb Res 1995;78:457-460
57. Vander Meer J, Hillege HL, Ascoop APL, et al. Aprotonin in aortocoronary bypass surgery: Increased risk of vein-graft occlusion and myocardial infarction? Thromb Haemost 1996;75:1-3